In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia. This study concluded that dasatinib is safe and provides positive long-term outcomes for these patients. Some background Dasatinib (Sprycel) is a targeted therapy...
Read More
In a nutshell The study evaluated how frequently patients with chronic lymphocytic leukemia (CLL) develop secondary blood cancers (SBC) in the real world. The main finding was that the occurrence of SBC, especially those in bone marrow, was rare among these patients. Some background Patients with CLL often face a poor prognosis due to other...
Read More
In a nutshell This study evaluated the outcomes of vaccination in children with acute lymphoblastic leukemia (ALL). This study found that children had less vaccine protection after chemotherapy. Some background Vaccines help the immune system recognize a pathogen using dead or weakened bacteria or viruses. Vaccines are not effective if someone’s...
Read More
In a nutshell This study looked at combining chemotherapy with dasatinib (Sprycel) to treat patients with acute myeloid leukemia (AML) with a CBF mutation. This study found that dasatinib was a safe and effective treatment for these patients. Some background AML is a cancer of immature blood cells called myeloid cells. Around 12% of AML cases...
Read MoreIn a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...
Read MoreIn a nutshell The study investigated the effects of switching treatment to nilotinib (Tasigna) after initial therapy with imatinib (Gleevec) in patients with chronic phase of chronic myeloid leukemia (CP-CML). The authors found that switching to nilotinib after imatinib initial treatment is convenient and effective in such patients. Some background...
Read MoreIn a nutshell This study aimed to investigate if venetoclax was safe and effective in older patients with relapsed/refractory chronic lymphocytic leukemia outside of clinical trials. This study concluded that venetoclax is safe and effective in these patients. Some background Chronic lymphocytic leukemia (CLL) is commonly diagnosed in older people....
Read MoreIn a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...
Read MoreIn a nutshell This study aimed to investigate if ibrutinib was safe and effective as a salvage treatment after stem cell transplant in patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective as a salvage treatment in these patients. Some background Allogeneic...
Read MoreIn a nutshell This study investigated preimplantation genetic testing for aneuploidy (PGT-A) for fertility preservation (FP). They found that PGT-A was useful in cancer patients attempting FP. Some background Assisted reproductive technology (ART) is used to treat infertility. It is also an important option for cancer patients. Cancer...
Read More
In a nutshell The study evaluated if the molecular response to Imatinib (Gleevec) is a proper way to judge treatment progress in Iranian patients with chronic-phase chronic myeloid leukemia (CP-CML). The main finding was that survival was improved in patients who had a better molecular response to imatinib. Some background Patients with...
Read MoreIn a nutshell The study investigated whether blinatumomab (Blincyto) can be used for salvage therapy before hematopoietic cell transplantation (HCT) in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The main finding was that blinatumomab can be safely and effectively used in patients with r/r B-ALL before HCT. Some...
Read More
